Related Experiment Video

Updated: Jul 15, 2026

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment
08:49

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

Published on: August 2, 2024

Troponin, B-type natriuretic peptides and outcomes in severe heart failure: differences between ischemic and dilated

Wayne L Miller1, Karen A Hartman, Mary F Burritt

  • 1Division of Cardiovascular Diseases, Biochemistry and Immunology, Mayo Clinic, Rochester, MN 55905, USA. miller.wayne@mayo.edu

Clinical Cardiology
|May 12, 2007
PubMed

Insights

Biomarker levels for troponin and B-type natriuretic peptide are higher in patients with ischemic cardiomyopathy (ISCM) compared to idiopathic dilated cardiomyopathy (IDCM). This finding correlates with increased cardiovascular mortality in ISCM patients.

Area of Science:

  • Cardiology
  • Biomarkers
  • Heart Failure Etiology

Background:

  • Ischemic (ISCM) and idiopathic dilated cardiomyopathies (IDCM) present differently in heart failure (HF).
  • Elevated troponin and B-type natriuretic peptides (BNP) are common in HF, but differences based on etiology are not well-established.
  • Understanding etiological differences in HF biomarkers is crucial for prognosis and treatment.

Purpose of the Study:

  • To quantitatively compare biomarker levels of troponin T, troponin I, BNP, and NT-proBNP between ISCM and IDCM in chronic HF patients.
  • To investigate potential differences in biomarker profiles based on the underlying cause of heart failure.

Main Methods:

  • Studied 40 patients hospitalized for acute heart failure (NYHA Class III-IV, LVEF 25%).
  • Collected blood samples for biomarker analysis (troponin T, troponin I, BNP, NT-proBNP) upon admission before treatment.
  • Compared biomarker levels between patients with ISCM (n=27) and IDCM (n=13).

Main Results:

  • ISCM patients exhibited significantly higher levels of cardiac troponin T (cTnT), cardiac troponin I (cTnI), and BNP compared to IDCM patients.
  • Cardiovascular mortality at 10 months was substantially higher in the ISCM group (48%) than in the IDCM group (23%).
  • Baseline clinical characteristics were similar, except for glomerular filtration rate (GFR).

Conclusions:

  • Acutely decompensated chronic heart failure patients show elevated troponin and BNP levels.
  • Higher biomarker elevations and cardiovascular mortality are observed in ISCM compared to IDCM.
  • Differential biomarker levels may reflect distinct disease pathogenesis and contribute to the poorer prognosis in ISCM.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...